GLP-1s have gone so far as to disrupt the food, clothing, and, of course, weight-loss industries. Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

It’s going to be an experiment to go off of it.” As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, ...

Dr. Jonathan Kaplan, a board-certified plastic surgeon from San Francisco, has amassed 1.6 million views on TikTok (@ realdrbae) with his warning: "Once you stop Ozempic, you will regain the weight." ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

Eli Lilly And Co (NYSE:LLY) experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick ...

One interesting distinction in the weight loss drug landscape is that of injectable drugs versus oral drugs. Lilly and Novo currently deliver their drugs Zepbound and Wevogy, via self-injections.

Weight-loss drugs like Wegovy and Zepbound are transforming the health of millions of people—and a new study hints that even more could benefit from the drugs’ other effects on the body.

In a court filing earlier this month, the FDA agreed to reconsider a decision last month to bar drug compounders from selling their versions of Eli Lilly's blockbuster weight loss and diabetes drugs.